| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
By altering MEFs' chromatin, CYT296 (250 nM, 72 h) increases the accessibility of Yamanaka factors and facilitates the reprogramming process [1]. A tiny drug called CYT296 (250 nM, 72 hours) can greatly enhance the production of iPSCs by preventing heterochromatin assembly in MEFs [1].
|
|---|---|
| ln Vivo |
The pluripotent CYT296 (10–15 4F– and 2F–iPSC clones, subcutaneous injection, once) iPSCs were produced in NOD-SCID animals[1].
|
| Cell Assay |
Immunofluorescence[1]
Cell Types: MEFs Tested Concentrations: 250 nM Incubation Duration: 72 h Experimental Results: diminished the number and total intensity of HP1α+ and H3K9me3+ foci in the nuclei of MEFs. Western Blot Analysis[1] Cell Types: MEFs Tested Concentrations: 250 nM Incubation Duration: 72 h Experimental Results: Speeded up the expression of Nanog during 4F-mediated reprogramming and appeared as early as day 8. diminished the protein level of HP1α during reprogramming. |
| Animal Protocol |
Animal/Disease Models: 4F- and 2F-iPSC clones mice[1]
Doses: 10-15 4F- and 2F -iPSC clones Route of Administration: subcutaneous (sc) injection Experimental Results: Obtained 6 out of 10 born mice from clone 4F-1 and 9 out of 15 born mice from clone 2F-1 were chimeras. |
| References |
[1]. Wei X, et al. Small molecule compound induces chromatin de-condensation and facilitates induced pluripotent stem cell generation. J Mol Cell Biol. 2014 Oct;6(5):409-20.
|
| Molecular Formula |
C18H16O2S
|
|---|---|
| Molecular Weight |
296.38
|
| CAS # |
1799392-31-6
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (337.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.44 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.44 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (8.44 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3740 mL | 16.8702 mL | 33.7405 mL | |
| 5 mM | 0.6748 mL | 3.3740 mL | 6.7481 mL | |
| 10 mM | 0.3374 mL | 1.6870 mL | 3.3740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
